AsianScientist (July 27, 2017) – To leverage each other’s strengths and accelerate the drug discovery process, Takeda Pharmaceutical Company Limited has teamed up with Schrödinger Incorporated, a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods. The multi-target research collaboration is directed at treating diseases that are aligned with Takeda’s core therapeutic areas of interest.
The unique collaboration will combine Schrödinger’s computer-aided drug discovery capabilities with Takeda’s deep therapeutic area knowledge and expertise in structural biology. Schrödinger will lead the multi-target discovery effort with its computational platform to guide the design of new chemical entities, while Takeda will complement Schrödinger’s efforts by providing protein crystal structures. Schrödinger will be responsible for its discovery costs.
“Takeda’s business model is focused on creating mutually beneficial partnerships that capitalize on the complementary capabilities of both parties in order to accelerate the discovery of new therapies for patients. In this case, Schrödinger is taking the lead role in discovery, with Takeda playing a supporting role, leveraging its in-house structural biology team and therapeutic area expertise,” said Dr. Stephen Hitchcock, Head of Research for Takeda.
“This alliance allows us the opportunity to fully exploit the power of our platform to accelerate the delivery of novel therapeutics to patients,” said Dr. Ramy Farid, Schrödinger’s president and chief executive officer.
———
Source: Takeda; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
